## 4 Discussion  
The findings of this randomized controlled trial highlight the therapeutic efficacy of _Elysium Naso-gola_, an isotonic saline solution enriched with mullen (_Verbascum thapsus_), thymme (_Tthymus vulgaris_), propolisis, and long-chain polyphosphates, in the management of pediatric AR. The significant reduction in symptom severity, as assessed using the I-NOSE questionnaire and VAS scale, underscores the formulation's potential as a safe and effective non-pharmacological intervention [26; 27]. These results align with existing evidence supporting the use of conventional saline irrigation for reducing nasal congestion and improving mucociliary clearance in upper respiratory infections [9]. Figure 2: Results of the VAS scale in the two study groups during this study. However, the enhanced efficacy observed in this study suggests that the additional bioactive compounds provide benefits beyond those of standard saline solutions. Thyme (_Thymus vulgaris_), a key component of _Elysium Nase-gola_, has demonstrated antimicrobial, mucolytic, and anti-inflammatory properties, which are beneficial for upper respiratory tract infections [11; 12; 28]. Essential oils derived from thyme have been shown to modulate pro-inflammatory cytokines and reduce bacterial and viral loads in respiratory infections [13]. Similarly, mulein (_Verbascum thupsus_) has been traditionally used for respiratory conditions due to its expectorant and anti-inflammatory effects [14]. A phytochemical study analyzed extracts of _Verbascum thapsus_, identifying the presence of saponins with expectorant properties that can help relieve symptoms in respiratory conditions [29]. Propolis, another active component, has been extensively studied for its antiviral, antibacterial, and immunomodulatory effects. Clinical and preclinical studies indicate that propolis extracts inhibit viral replication, modulate immune responses, and reduce inflammation, making it a promising adjunct for upper respiratory infections [15; 16]. The inclusion of long-chain polyphosphates in this formulation represents an innovative aspect, as these compounds have been found to enhance mucosal barrier integrity, inhibit bacterial adhesion, and exert antimicrobial properties. Emerging evidence suggests that polyphosphates contribute to the protection of epithelial surfaces in the respiratory tract and could play a crucial role in reducing infection susceptibility [24]. The absence of adverse events in this study supports the safety of _\"Elysium Nase-gola\"_, which is consistent with the literature indicating that natural compounds are generally well tolerated and present minimal side effects compared to synthetic drugs [17]. Furthermore, the rapid symptom alleviation observed in the active treatment group suggests that this formulation could shorten the duration of illness, potentially mitigating the economic burden of AR, which includes direct healthcare costs and indirect losses due to caregiver absenteeism [3; 5]. Despite the promising results, this study presents several limitations. Firstly, the relatively small sample size restricts the generalizability of our findings. Additionally, the short follow-up period of only 10 days does not permit drawing definitive conclusions regarding the long-term safety and efficacy of repeated treatment use. Given that AR can exhibit recurrence or rebound effects after therapy cessation, future research should adopt a longer observational period (e.g., 4-6 weeks) to accurately assess sustained therapeutic outcomes and potential delayed adverse effects. Another limitation is the exclusive enrollment of Caucasian pediatric patients aged between 4 and 14 years. This demographic constraint limits the applicability of our results to other ethnic groups and broader pediatric age ranges, such as toddlers and adolescents. Variations in immune response, nasal physiology, and anatomical structures among diverse populations may significantly affect therapeutic efficacy and tolerability.